Retraction notice to “Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial” (Fertility and Sterility (2014) 102(5) (1357–1363.e3), (S0015028214020226), (10.1016/j.fertnstert.2014.07.1251));Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: A double-blind, randomized, parallel, placebo-controlled trial

Fertility and Sterility

Volumn 102, Issue 5, 2014, Pages 1357-1363.e3

  Kumar, Ashok ^a   Begum, Nargis ^a   Prasad, Sudha ^a   Aggarwal, Sarita ^a   Sharma, Shashi ^b  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

Author keywords

Dydrogesterone; Pregnancy outcome; Recurrent pregnancy loss; Th1 cytokines; Th2 cytokines

Indexed keywords

DYDROGESTERONE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; PHOSPHOLIPID ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; GESTAGEN;

ADULT; ARTICLE; BIRTH WEIGHT; CELL LEVEL; CESAREAN SECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; FEMALE; FIRST TRIMESTER PREGNANCY; FOLLOW UP; GESTATIONAL AGE; HUMAN; HUMAN CELL; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MODULATION; NEWBORN; OUTCOME ASSESSMENT; PARALLEL DESIGN; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT ABORTION; SMALL FOR DATE INFANT; TH1 CELL; TH1 TH2 BALANCE; ABORTION, HABITUAL; IMMUNOLOGY; INDIA; ORAL DRUG ADMINISTRATION; PLACEBO EFFECT; PREGNANCY; PREVALENCE; RISK FACTOR; TREATMENT OUTCOME;

ABORTION, HABITUAL; ADMINISTRATION, ORAL; ADULT; CYTOKINES; DOUBLE-BLIND METHOD; DYDROGESTERONE; FEMALE; HUMANS; INDIA; PLACEBO EFFECT; PREGNANCY; PREVALENCE; PROGESTINS; RISK FACTORS; TH1-TH2 BALANCE; TREATMENT OUTCOME;

EID: 84922011944     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2023.02.001     Document Type: Erratum

References (32)

1. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. Brit Med J 2000;320:1708-12.
2. American College of Obstetricians and Gynecologists (ACOG). Early pregnancy loss. ACOG Tech Bull No. 212. Washington, DC: ACOG; 1995.
3. Shormila R, Knapp LA. Human reproductive failure I: immunological factors. Hum Reprod Update 2000;7:113-34.
4. Szekeres-Bartho J. Immunological relationship between the mother and the fetus. Intern Rev Immunol 2002;21:471-96.
5. Raghupathy R, Makhseed M, Azizieh F, Omu A, Gupta M, Farhat R. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod 2000;15:713-8.
6. Piccinni MP, Giudizi MG, Biagiotti R, Beloni L, Giannarini L, Sampognaro S, et al. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established T cell clones. J Immunol 1995;155:128-33.
7. Choi BC, Polgar K, Xiao L, Hill JA. Progesterone inhibits in vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 2000;15(Suppl 1):46-59.
8. Szekeres-Bartho J, Par G, Dombay GY, Smart YC, Volgyi Z. The anti-abortive effect of PIBF in mice is manifested by modulating NK activity. Cell Immunol 1997;177:194-9.
9. Raghupathy R, Al Mutawa E, Makhseed M, Azizieh F, Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. Brit J Obst Gynecol 2005;112:1096-101.
10. El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 2005;97:431-4.
11. Omar MH, Mashita MK, Lim PS, Jamil MA. Dydrogesterone in threatened abortion: pregnancy outcome. J Steroid Biochem Molec Biol 2005;97:421-5.
12. Kalinka J, Radwan M. The impact of dydrogesterone supplementation on serum cytokine profile in women with threatened abortion. Am J Reprod Immunol 2006;55:115-21.
13. Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol 2012;28:983-90.
14. Raghupathy R, Kalinka J. Cytokine imbalance in pregnancy complications and its modulation. Front Biosci 2008;13:985-94.
15. Elovitz MA, Mrinalini C. The use of progestational agents for preterm birth: lesson from a mouse model. Am J Obstet Gynecol 2006;195:1004-10.
16. Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 2005;105:273-9.
17. Mackenzie R, Walker M, Armson A, Hannah ME. Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol 2006;194:1234-42.
18. Daya S, Ward S, Burrows E. Progesterone profiles in luteal phase defect cycles and outcome of progesterone treatment in patients with recurrent spontaneous abortion. Am J Obstet Gynecol 1988;158:225-32.
19. Raghupathy R, Makhseed M, Azizieh F, Hassan N, Al-Azemi M, Al-Shamali E. Maternal Th1- and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions. Cell Immunol 1999;196:122-30.
20. Eblen AC, Gercel-Taylor C, Shields LB, Sanfilippo JS, Nakajima ST, Taylor DD. Alterations in humoral immune responses associated with recurrent pregnancy loss. Fertil Steril 2000;73:305-13.
21. Faust Z, Laskarin G, Rukavina D, Szekeres-Bartho J. Progesterone-induced blocking factor inhibits degranulation of natural killer cells. Am J Reprod Immunol 1999;42:71-5.
22. Polgár B, Nagy E, Mikó E, Varga P, Szekeres-Barthó J. Urinary progesterone induced blocking factor concentration is related to pregnancy outcome. Biol Reprod 2004;71:1699-705.
23. Arck PC, Rücke M, Rose M, Szekeres-Bartho J, Douglas AJ, Pritsch M, et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women. Reprod Biomed Online 2008;17:101-13.
24. Blois SM, Joachim R, Kandil J, Margni R, Tometten M, Klapp BF, et al. Depletion of CD8+ cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering the Th1/Th2 cytokine profile. J Immunol 2004;172:5893-9.
25. Hidalgo A, Suzano RC, Revuelta MP, Sanchez-Diaz C, Baamonde A, Cantabrana B. Calcium and depolarization-dependent effect of pregnenolone derivatives on uterine smooth muscle. Gen Pharmacol 1996;27:879-85.
26. Eskes TK, Hein PR, Stolte LA, Kars-Villanueva EB, Crone A, Braaksma JT. Influence of dydrogesterone on the activity of the nonpregnant human uterus. Am J Obstet Gynecol 1970;106:1235-44.
27. Benifla JL, Dumont M, Levardon M, Foucher E, Cadiot G, Crenn-Hebert C, et al. Effects of micronized natural progesterone on the liver during the third trimester of pregnancy. Contracept Fertil Sex 1997;25:165-9.
28. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW. Classification and pharmacology of progestins. Maturitas 2003;46(Suppl 1):S7-16.
29. Hudic I, Szekeres-Bartho J, Fatusic Z, Stray-Pedersen B, Dizdarevic-Hudic L, Latifagic A, et al. Dydrogesterone supplementation in women with threatened preterm delivery - the impact on cytokine profile, hormone profile, and progesterone-induced blocking factor. Reprod Immunol 2011;92:103-7.
30. Li TC, Ding SH, Anstie B, Tuckerman E, Wood K, Laird S. Use of human menopausal gonadotropins in the management of endometrial defects associated with recurrent miscarriage: preliminary report. Fertil Steril 2001;75:434-7.
31. Raghupathy R. Manipulation of cytokine production profiles as a therapeutic approach for immunologic pregnancy loss. Indian J Biochem Biophys 2008;45:229-36.
32. Raghupathy R, Al Mutawa E, Makhseed M, Al-Azemi M, Azizieh F. Redirection of cytokine production by lymphocytes from women with pre-term delivery by dydrogesterone. Am J Reprod Immunol 2007;58:31-8.